Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women With Low Bone Mineral Density

NCT06577935 is registered in ClinicalTrials.gov with Angitia Biopharmaceuticals as lead sponsor.

NCT NCT06577935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women With Low Bone Mineral Density
Lead sponsor
Angitia Biopharmaceuticals
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2024
Completion date
March 31, 2028
Enrollment
379 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis